Cardiothrombosis Research Laboratory, LR12SP16 University of Monastir, Monastir, 5000, Tunisia.
Laboratory of Human Genome and Multifactorial Diseases, Faculty of Pharmacy of Monastir, University of Monastir, LR12ES07, Monastir, Tunisia.
BMC Cardiovasc Disord. 2023 Nov 28;23(1):586. doi: 10.1186/s12872-023-03570-8.
Cytokines play a potential role in atherosclerosis pathogenesis and progression. We investigated the association of interleukin-6 (IL-6) with the angiographic severity of coronary artery disease (CAD).
Three hundred ten angiografically diagnosed CAD patients and 210 controls were enrolled in this study. CAD patients were stratified according to IL-6 cut-off value into high levels IL-6 group (≥ 9.5 pg/mL) and low levels IL-6 group (< 9.5 pg/mL). The severity of CAD was assessed according to Gensini score (GS), artery stenosis degree and the number of vessels involved. The mean age was 60.3 ± 11.0 years.
The level of IL-6 in patients was increased compared to controls and ranged from 1.5 to 3640.0 pg/mL. High levels of IL-6 were significantly associated with high levels of GS (> 40) but not with stenosis degree and vessel score. GS levels were significantly more elevated in patients with high levels of IL-6 group than in low IL6 levels patients (60.6 ± 39.5 vs 46.7 ± 37.2; p = 0.027). The analysis of the ROC curve performed in myocardial infarction patients showed that IL-6 (AUC: 0.941 (CI 95% 0.886, 0.997; p < 0.001) could be a powerful predictor marker in evaluating the infarct size after myocardial infarction when compared to myonecrosis biomarkers.
IL-6 levels were associated with the severity of CAD assessed by the GS. Based on the highest levels of IL-6 measured in patients with STEMI, our study strongly suggests that IL-6 could be a powerful marker in evaluating the myocardial necrosis.
ClinicalTrials.gov Number: NCT03075566 (09/03/2017).
细胞因子在动脉粥样硬化的发病机制和进展中发挥着潜在作用。我们研究了白细胞介素 6(IL-6)与冠状动脉疾病(CAD)的血管造影严重程度之间的关系。
本研究纳入了 310 例经血管造影诊断为 CAD 的患者和 210 例对照者。根据 IL-6 截断值,将 CAD 患者分为高 IL-6 组(≥9.5pg/mL)和低 IL-6 组(<9.5pg/mL)。根据 Gensini 评分(GS)、动脉狭窄程度和受累血管数评估 CAD 的严重程度。平均年龄为 60.3±11.0 岁。
与对照组相比,患者的 IL-6 水平升高,范围为 1.5 至 3640.0pg/mL。高水平的 IL-6 与高 GS(>40)显著相关,但与狭窄程度和血管评分无关。与低 IL-6 组相比,高 IL-6 组患者的 GS 水平显著升高(60.6±39.5 与 46.7±37.2;p=0.027)。对心肌梗死患者的 ROC 曲线分析表明,与心肌坏死标志物相比,IL-6(AUC:0.941(CI 95%,0.886,0.997;p<0.001)在评估心肌梗死后的梗死面积时可以作为一种强大的预测标志物。
IL-6 水平与通过 GS 评估的 CAD 严重程度相关。基于 STEMI 患者中测量到的最高 IL-6 水平,我们的研究强烈表明 IL-6 可能是评估心肌坏死的有力标志物。
ClinicalTrials.gov 编号:NCT03075566(2017 年 9 月 3 日)。